Excessive Sweat Sufferers Are Ditching Antiperspirant for Botox Injections

Excessive Sweat Sufferers Are Ditching Antiperspirant for Botox Injections

Excessive sweating can be more than an inconvenience: primary hyperhidrosis affects an estimated 4.8% of people in the United States, according to a 2016 study in the Archives of Dermatological Research. For people whose underarm sweating persists despite correctly used antiperspirants, botulinum toxin injections—often called Botox—are an established treatment option, not a universal replacement. Clinical guidance supports considering injections when topical treatments are insufficient, while treatment choice depends on the affected area, symptom burden, medical history, cost, and willingness to repeat treatment. Here is how hyperhidrosis is defined, what Botox can do, how it compares with antiperspirants, and what patients should discuss with a clinician.

Primary hyperhidrosis and excessive sweating

Hyperhidrosis means sweating beyond what the body needs to regulate temperature. The International Hyperhidrosis Society describes primary focal hyperhidrosis as excessive sweating in particular areas—commonly the underarms, palms, soles, or face—that is not explained by another medical condition or medication. It can interfere with work, social activities, clothing choices, and emotional well-being.

Primary focal and secondary hyperhidrosis

Primary focal hyperhidrosis usually affects specific, often symmetrical body sites and commonly begins in childhood or adolescence. Secondary hyperhidrosis is sweating associated with an underlying cause, such as a health condition or medication; it may be more generalized or begin later in life. A clinician can assess the pattern and history and decide whether evaluation for a secondary cause is needed.

The distinction matters because treatments aimed at local sweat glands may help focal symptoms but do not address an underlying cause. Sudden new sweating, night sweats, or sweating accompanied by other concerning symptoms warrants medical assessment rather than self-diagnosis.

How common and consequential is it?

A U.S. population study by Doolittle and colleagues estimated hyperhidrosis prevalence at 4.8%, or about 15.3 million people based on the study’s population estimate. The authors also found that many affected people had not discussed the condition with a health professional. These figures describe the study’s survey-based estimate, not a real-time count, but they help explain why excessive sweating may be undertreated.

Underarm sweating can stain clothing and prompt frequent changes or avoidance of certain fabrics. The severity is not measured only by sweat volume: the effect on daily life and the person’s response to treatment are also important.

Hyperhidrosis treatment and the role of antiperspirants

The American Academy of Dermatology and the International Hyperhidrosis Society describe treatment as a stepwise, individualized process. Options include topical antiperspirants, prescription medicines, device-based treatments, injections, and—in selected severe cases—surgery. The appropriate choice depends on the body site and previous results.

Antiperspirants are often the first step

Antiperspirants reduce sweat reaching the skin by temporarily blocking or narrowing sweat ducts. They are different from deodorants, which chiefly address odor. Aluminum-salt antiperspirants are commonly recommended as an initial treatment; prescription-strength products may be considered when over-the-counter products do not control symptoms.

Application technique can affect results. Dermatology guidance commonly advises applying antiperspirant to completely dry skin, often at bedtime, and following the product or prescriber’s directions. Skin irritation is possible, and a clinician can suggest adjustments if it occurs. People who have tried an antiperspirant inconsistently or only on damp skin may not have had a fair trial.

When injections enter the discussion

Botulinum toxin type A is a prescription treatment that temporarily blocks nerve signals involved in activating sweat glands. The U.S. Food and Drug Administration (FDA) approves Botox for severe primary axillary hyperhidrosis—excessive underarm sweating—when topical agents have not worked adequately or are not tolerated. Use for other body sites may be off-label and should be discussed with a qualified clinician.

So the trend is better understood as some patients moving to injections after inadequate topical control, rather than antiperspirants being obsolete. Antiperspirants remain convenient and noninvasive; injections may be considered when underarm symptoms remain disruptive despite appropriate use.

Botox injections for excessive underarm sweating

Botox for hyperhidrosis is a clinician-administered treatment delivered as multiple small injections into the affected underarm skin. The FDA prescribing information explains that the medicine acts locally to inhibit acetylcholine release at the nerve endings that stimulate sweat glands. It does not permanently remove the glands or cure the underlying tendency to sweat.

Effectiveness and duration

In the FDA’s clinical studies of severe primary axillary hyperhidrosis, participants receiving Botox had a significantly greater reduction in sweating than those receiving placebo. In one study, 75% of treated participants achieved at least a 50% reduction in sweat production at four weeks, compared with 25% of placebo recipients. Individual results vary, and a response does not necessarily mean complete dryness.

The effect is temporary. FDA labeling reports a median duration of response of approximately 201 days in the principal study, with some people requiring repeat treatment sooner or later. That means continued benefit generally involves follow-up and possible repeat injections, rather than a one-time procedure.

What the procedure involves

A clinician confirms the treatment area and may use a starch-iodine test to map active sweating. The underarm is cleaned, and small injections are placed across the area. Discomfort, bruising, or tenderness can occur; some clinicians use cooling or other comfort measures. Patients should ask who will perform the procedure, what preparation is required, and how results will be assessed.

Improvement is not necessarily immediate. FDA study data assess response over the weeks after treatment, so patients should follow the clinician’s guidance about when to judge the result and when to return.

Risks, precautions, and candidacy

Common adverse effects reported in FDA labeling for underarm treatment include injection-site pain or bleeding and non-underarm sweating. As with other botulinum toxin products, the FDA warns about the possibility of toxin effects spreading beyond the injection area, which can cause serious symptoms such as generalized weakness, vision problems, difficulty swallowing, or difficulty breathing. Such symptoms require urgent medical attention.

Patients should tell the prescriber about medical conditions, medications, previous botulinum toxin treatment, and pregnancy or breastfeeding. The FDA label lists certain contraindications, including infection at the proposed injection site and known hypersensitivity to botulinum toxin or product ingredients. A licensed clinician should review the current prescribing information and determine whether treatment is appropriate.

Comparing Botox with other hyperhidrosis options

No single treatment is best for everyone. Antiperspirants are easy to use and avoid injections, while Botox can provide months of underarm symptom relief for some patients but involves a clinical procedure, cost, and potential repeat visits. Other approaches may be more suitable depending on whether sweating affects the underarms, hands, feet, or multiple areas.

Other options for focal sweating

For hands and feet, iontophoresis uses a mild electrical current through water to reduce sweating and often requires repeated sessions. Prescription oral anticholinergic medicines can reduce sweating more broadly, but may cause effects such as dry mouth, constipation, blurred vision, or difficulty urinating. For underarms, clinicians may also discuss microwave-based sweat-gland treatment. These approaches have different benefits, limitations, and risks.

Choosing a treatment with a clinician

A practical discussion can cover the areas affected, how often sweating occurs, its impact on daily activities, products already tried, and any relevant medical history. Patients can ask whether their pattern suggests primary or secondary hyperhidrosis, whether they have used antiperspirant correctly, what treatment is approved for their affected site, and how benefit, side effects, cost, and maintenance compare.

A symptom diary or a simple record of clothing changes, disrupted activities, and treatment response can help make the consultation more concrete. The goal is not necessarily to eliminate every trace of sweat, which is a normal bodily function, but to achieve a meaningful improvement safely.

Conclusion: choosing relief based on evidence

Hyperhidrosis is common and can substantially affect quality of life. Antiperspirants remain a standard first approach, while FDA-approved Botox injections are an evidence-supported option for severe underarm sweating when topical treatment has not worked adequately or cannot be tolerated. The clinical evidence shows meaningful sweat reduction for many patients, but results are temporary and treatment carries risks and costs.

People troubled by persistent sweating should consider speaking with a dermatologist or other qualified health professional rather than abandoning treatment without guidance. Further reading from the FDA, the American Academy of Dermatology, and the International Hyperhidrosis Society can help prepare patients to compare options and make an informed plan.

Sources: Doolittle, J. et al., “Hyperhidrosis: An Update on Prevalence and Severity in the United States,” Archives of Dermatological Research, 2016, https://pubmed.ncbi.nlm.nih.gov/26530333/; U.S. Food and Drug Administration, BOTOX (onabotulinumtoxinA) Prescribing Information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/103000s5327lbl.pdf; American Academy of Dermatology, Hyperhidrosis: Diagnosis and Treatment, https://www.aad.org/public/diseases/a-z/hyperhidrosis-treatment; International Hyperhidrosis Society, Hyperhidrosis: Causes, Impact and Treatment, https://www.sweathelp.org/